BlackRock Reports 3.47M Shares (5.7%) of Mirum

BlackRock, Inc. reports beneficial ownership of 3,465,559 shares of Mirum Pharmaceuticals, Inc. common stock, representing 5.7% of the class.

Rhea-AI Filing Summary

BlackRock, Inc. reports beneficial ownership of 3,465,559 shares of Mirum Pharmaceuticals, Inc. common stock, representing 5.7% of the class. The filing shows sole voting power over 3,404,101 shares and sole dispositive power over 3,465,559 shares. The Schedule 13G/A is signed by a BlackRock Managing Director on 04/27/2026.

Insights

Corporate Governance Analyst

BlackRock reports over 5% stake with sole voting and dispositive control.

BlackRock's Schedule 13G/A lists ownership of 3,465,559 shares (5.7%) and sole voting power for 3,404,101 shares. The filing attributes holdings to Reporting Business Units within BlackRock under SEC guidance.

Ownership at this level triggers public disclosure but is typical for institutional investors; subsequent filings would show any material changes.

Institutional Investor Relations

Filing clarifies voting and disposition authorities across BlackRock units.

The Schedule 13G/A differentiates sole voting and sole dispositive powers and references Exhibit 99 for subsidiary identification. This helps identify which internal business units hold or direct the securities.

Stake size and disclosed powers are factual; any trading activity or intent is not stated here.

Key Figures

Beneficially owned: 3,465,559 shares Percent of class: 5.7% Sole voting power: 3,404,101 shares +2 more

5 metrics

Beneficially owned 3,465,559 shares Amount beneficially owned (Item 4)

Percent of class 5.7% Percent of class (Item 4)

Sole voting power 3,404,101 shares Sole power to vote or to direct the vote (Item 4(c)(i))

Sole dispositive power 3,465,559 shares Sole power to dispose or direct disposition (Item 4(c)(iii))

Signature date 04/27/2026 Schedule signed by Managing Director

Key Terms

Schedule 13G/A, Sole dispositive power, Reporting Business Units, Exhibit 99

4 terms

Schedule 13G/A regulatory

"Amendment No. 2 Schedule 13G/A reporting beneficial ownership"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Sole dispositive power financial

"Sole power to dispose or to direct the disposition of: 3465559"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Reporting Business Units regulatory

"beneficially owned by certain business units (collectively, the "Reporting Business Units")"

Exhibit 99 regulatory

"See Exhibit 99 Item 7 identification of relevant subsidiary"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does BlackRock hold in Mirum Pharmaceuticals (MIRM)?

BlackRock beneficially owns 3,465,559 shares, equal to 5.7%. The Schedule 13G/A lists 3,465,559 shares and states this represents 5.7% of Mirum's common stock as reported in the filing.

How much voting power does BlackRock report for MIRM?

BlackRock reports sole voting power over 3,404,101 shares. The filing breaks out voting and dispositive powers, showing sole voting power of 3,404,101 shares in Item 4.

Does BlackRock report shared voting or dispositive power for MIRM?

No shared voting or dispositive power is reported. The Schedule 13G/A shows 0 for both shared voting power and shared dispositive power in Item 4 of the filing.

Who signed the Schedule 13G/A for BlackRock and when?

The filing is signed by Spencer Fleming, Managing Director, on 04/27/2026. The signature block at the end of the document lists the signer and date.

Does the filing identify which BlackRock unit holds the shares?

The filing attributes holdings to Reporting Business Units within BlackRock. It states the amounts reflect securities beneficially owned by certain business units and references Exhibit 99 for subsidiary identification.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/27/2026 - 04:12 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Mirum Pharmaceuticals, Inc

(Name of Issuer)

Common Stock

(Title of Class of Securities)

604749101

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 604749101

1

Names of Reporting Persons

BlackRock, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,404,101.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,465,559.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,465,559.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.7 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Mirum Pharmaceuticals, Inc
(b)	Address of issuer's principal executive offices: 989 EAST HILLSDALE BOULEVARD, SUITE 300 FOSTER CITY CA 94404
Item 2.
(a)	Name of person filing: BlackRock, Inc. In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release.
(b)	Address or principal business office or, if none, residence: BlackRock, Inc., 50 Hudson Yards New York, NY 10001
(c)	Citizenship: See Item 4 of Cover Page
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 604749101
Item 4.	Ownership
(a)	Amount beneficially owned: 3465559
(b)	Percent of class: 5.7 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 3404101
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 3465559
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of Mirum Pharmaceuticals, Inc. No one person's interest in the common stock of Mirum Pharmaceuticals, Inc is more than five percent of the total outstanding common shares.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit 99
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BlackRock, Inc.

Signature:	Spencer Fleming
Name/Title:	Managing Director
Date:	04/27/2026

Exhibit Information

Exhibit 24: Power of Attorney Exhibit 99: Item 7